25 results about "Level insulin" patented technology

The present invention relates to compounds having antidiabetic activity, their preparation methods and uses. The compounds are analogues of diprotin A, have strong antidiabetic activity, belong to DPP-IV inhibitors, can improve blood insulin levels, and open up a new way for the treatment of diabetes. Applying the compounds to the preparation of foods, health products and drugs for preventing and / or treating diabetes has high social value and great significance.

The invention relates to the technical field of medical health, and particularly discloses a polycystic ovarian syndrome typing management system based on big data, the system integrates insulin level and LH / FSH ratio time sequence data of a patient, and adopts zero sequence processing, first order difference and time frequency analysis methods to extract metabolism and endocrine characteristics; and a comprehensive health feature vector is constructed through fusion and is input into a risk prediction model based on Bayesian network training, so that accurate identification of the type of the polycystic ovarian syndrome is realized, further, the system dynamically generates a personalized intervention scheme according to an identification result, and doctor-patient information synchronization and continuous optimization are realized through a cloud platform. By means of the method, the accuracy and scientificity of polycystic ovarian syndrome type typing are improved, individualized and intelligent disease management is achieved, and the method has good clinical application prospects and popularization value.

The invention belongs to the field of insulin infusion devices, and discloses an intelligent insulin infusion device for diabetic patients and a blood glucose control method.The device comprises a blood glucose monitoring module, an intelligent insulin infusion module, an AI control center, a user interaction module and a safety monitoring module. The DNN model can accurately predict the short-term blood glucose trend, and the response speed and accuracy of insulin infusion are remarkably improved; a dynamic adjustment algorithm dynamically adjusts the insulin dosage according to individual differences of patients and real-time data, and the risk of complications is reduced; the calculation and response time is reduced through combination of the model and the algorithm, and millisecond-level insulin infusion control is achieved; the system monitors and corrects an insulin infusion strategy in real time, reduces the risk of hypoglycemia and infusion failure, and ensures the safety of a patient. According to the invention, the living quality and the blood glucose management level of the diabetic patient are obviously improved, and meanwhile, the application and development of the intelligent medical technology in chronic disease management are promoted.

The invention belongs to the technical field of food processing, and particularly relates to a product with peony peptide and ginseng peptide as main raw materials and a preparation method of the product. According to the invention, leftovers such as ginseng root hair and peony seed meal are used as raw materials, so that the production cost is greatly reduced, and the prepared product is presented in the form of a solid beverage and is convenient to carry and drink; the ginseng peptide is prepared by adopting a steam explosion and biological enzymolysis technology, the peony peptide is prepared by adopting a microbial fermentation mode, the molecular weight of the polypeptide is reduced, digestion and absorption are facilitated, meanwhile, the yield and oxidation resistance of the peptide are improved by adopting the microbial fermentation mode, the highest yield can reach 45.5%, and the highest oxidation resistance can reach 72.5%; besides, isomaltulose is also added while the bovine bone collagen peptide powder, the ginseng peptide powder and the peony peptide powder are adopted, so that the taste of the product is improved, the reconstituability of the product is improved, the fluctuation of blood sugar and insulin level is not caused after the product is taken, and the product can also be drunk by diabetics.

The present invention discloses applications and methods of Leuconostoc mesenteroides, relating to the field of microbial technology. Leuconostoc mesenteroides can be used to prepare phytic acid and improve non-alcoholic fatty liver disease, increased liver weight, elevated blood lipids, elevated blood sugar, elevated serum lipopolysaccharide levels, elevated serum insulin levels, inflammatory responses, and elevated triglyceride levels in the liver caused by a high-fat, high-sugar diet, and inhibit the release of the pro-inflammatory cytokine lipopolysaccharide.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The present invention belongs to the field of functional foods, and specifically relates to a composition for lowering glucose and stabilizing an insulin level, a preparation method therefor, and use thereof. The composition of the present invention comprises a component I and a component II. The component I is cyclodextrin and a derivative thereof, the component II is naringenin and a derivative thereof, and the mass ratio of the component I to the component II is (0.1-100):(0.01-1). After being eaten with a meal or added to food, especially high-carbohydrate food, the composition of the present invention can significantly maintain the stability of the insulin level in the body while significantly controlling the postprandial blood glucose level. Long-term use can achieve the effects of stabilizing triglyceride, low-density lipoprotein, and high-density lipoprotein levels.

The present invention provides a powdered mixture comprising a non-dairy whipped topping, an isolated protein powder, and a plant-based sweetener that does not affect blood sugar or insulin levels. Importantly, the confection can easily be made at home using only water to reconstitute the powdered ingredients and comes in a variety of flavors. The confections disclosed herein can be configured in a solid form, a powdered form, a frozen confection, or as a semisolid or frozen beverage.

Disclosed is a meal detection and meal size estimation machine learning technology. In some embodiments, the techniques entail applying to a trained multioutput neural network model a set of input features, the set of input features representing glucoregulatory management data, insulin on board, and time of day, the trained multioutput neural network model representing multiple fully connected layers and an output layer formed from first and second branches, the first branch providing a meal detection output and the second branch providing a carbohydrate estimation output; receiving from the meal detection output a meal detection indication; and receiving from the carbohydrate estimation output a meal size estimation.

The invention provides application of an allium mongolicum extract. The allium mongolicum extract is used for preparing a feed for improving metabolism-related fatty liver diseases. The allium mongolicum extract disclosed by the invention is derived from natural plant compounds, has relatively high safety, can be used for reducing blood sugar and insulin levels of serum, reducing biochemical index levels of the serum and improving fatty degeneration of the liver, and exerts a positive protection effect on metabolism-related fatty liver diseases by cooperatively regulating lipid metabolism-related genes; the method has guiding significance for subsequent further development and utilization.

Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.

Described herein are methods of treatment of metabolic syndrome using Cannabis Plant Material to reduce fasting glucose and insulin and lower the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index to mitigate metabolic syndrome and associated Type II Diabetes, Coronary Heart Disease, and Stroke, pharmacological compounds for same and methods for making the pharmacological compounds.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

The present application relates to a compound with anti-diabetic activity and its application, the compound is an analogue of diprotin A, the compound has strong anti-diabetic activity, belongs to DPP-IV inhibitor, can improve blood insulin level, opens a new way for the treatment of diabetes, and the compound is applied to the preparation of a medicine for preventing or / and treating diabetes, has high social value and important significance.

The invention relates to the technical field of gestational diabetes mellitus detection, and discloses a gestational diabetes mellitus serum marker detection data analysis system. The system comprises a serum biochemical data acquisition module, a detection device is used for acquiring a serum sample of a pregnant woman, and a serum biochemical data set containing blood sugar concentration, insulin level and glycosylated hemoglobin indexes is constructed; a multi-dimensional index integration module combines a historical detection time sequence and the physiological parameter information of the current detection time period to generate an integrated data set containing time dimension correlation features; the abnormal risk analysis module processes the time dimension correlation features in the integrated data set, and calculates the risk deviation value of gestational diabetes in the current detection period; when the risk deviation value is abnormal, the risk grading module generates a plurality of candidate intervention classification schemes based on the serum biochemical data set, and outputs the intervention influence degree of each candidate scheme; and an intervention scheme generation module screens the candidate scheme with the lowest intervention influence degree and generates an optimal intervention classification scheme in the current detection time period.

The invention provides an application of eplerenone in preparation of a medicine for treating type 1 diabetes mellitus. The application finds that eplerenone can be used for effectively treating type 1 diabetes mellitus: reducing the blood glucose level of a type 1 diabetes mellitus model mouse, increasing the serum insulin level and the serum C peptide level, and improving the survival rate of the mouse.

A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.

The invention provides a traditional Chinese medicine composition for treating metabolic dysfunction related fatty liver diseases complicated with obstructive sleep apnea as well as a preparation method and application thereof, and particularly belongs to the technical field of medicines. The traditional Chinese medicine composition comprises rhizoma pinellinae praeparata, herba artemisiae scopariae, rhizoma acori graminei, pogostemon cablin, rhizoma atractylodis macrocephalae, pericarpium citri reticulatae, hawthorn, lotus leaves, rhizoma alismatis, radix curcumae, peach kernels, salvia miltiorrhiza, herba lycopi, bamboo shavings, immature bitter orange stir-fried with bran and poria cocos. The traditional Chinese medicine composition has a treatment effect on metabolic dysfunction related fatty liver diseases combined with obstructive sleep apnea, can significantly reduce BMI, body fat and waist-hip ratio of clinical patients, improves ALT, CAP values, AHI, blood fat, fasting blood-glucose and insulin levels, and has the effects of protecting liver, reducing lipid, improving apnea, improving metabolism and the like.

The present invention provides a powdered mixture comprising a non-dairy whipped topping, an isolated protein powder, and a plant-based sweetener that does not affect blood sugar or insulin levels. Importantly, the confection can easily be made at home using only water to reconstitute the powdered ingredients and comes in a variety of flavors. The confections disclosed herein can be configured in a solid form, a powdered form, a frozen confection, or as a semisolid or frozen beverage.

Disclosed herein are techniques related to automatic real-time meal detection. In some embodiments, the techniques involve obtaining a plurality of glucose concentration values and a plurality of plasma insulin concentration estimations, each glucose concentration value corresponding with a respective plasma insulin concentration estimation; generating an output based on applying a meal detection model to the plurality of glucose concentration values and the plurality of plasma insulin concentration estimations; and determining, based on the output, that a glucose concentration value of the plurality of glucose concentration values corresponds to an ongoing glycemic response to a meal.

The present invention generally relates to novel multi - agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, such as those that can be alleviated by control of weight loss, plasma glucose and lipid levels, insulin levels, and / or insulin secretion, positive inotropic action, reduction of catabolism, deceleration of gastric emptying, and prevention of neurodegeneration. Such conditions and disorders include, but are not limited to, food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels and / or insulin secretion, positive inotropic action, reduction of catabolism, deceleration of gastric emptying, obesity, diabetes and diabetes - related conditions, control of liver fat - related inflammation and damage. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, and rare genetic disorders of obesity, such as Prader - Willi syndrome, critical care, insulin resistance and its disorders, such as polycystic ovary syndrome, obesity, all types of diabetes including type 1, type 2 and gestational diabetes, and CNS disorders, such as prevention of neurodegeneration, depression, alcoholism, Alzheimer's disease and Parkinson's disease, and non - alcoholic steatohepatitis (NASH).

The invention belongs to the technical field of health food materials, and particularly relates to low-GI coarse cereal bean meal replacement powder and application thereof. The formula of the low-G I coarse cereal bean meal replacement powder comprises the following raw materials in parts by mass: 23.612 parts of pouch bean powder, 13.524 parts of red bean powder, 3.998 parts of Chinese wolfberry fruits, 15 parts of oat powder, 15 parts of coix seed powder, 15 parts of quinoa powder and 14 parts of flaxseed powder. The invention explores the influence of the low-G I coarse cereal bean meal replacement powder on glycolipid metabolism and inflammatory factors of rats suffering from type 2 diabetes mellitus. After the coarse cereal bean meal replacement powder is taken, the fasting blood glucose level of rats suffering from type 2 diabetes mellitus is obviously reduced, the insulin level is obviously increased, the glucagon and glycosylated hemoglobin levels are obviously reduced, and the insulin resistance is obviously improved; the TC, TG and LDL-c levels of rats with type 2 diabetes mellitus are obviously reduced, the HDL-c level is obviously increased, and the dyslipidemia is obviously improved; the inflammatory response and liver and kidney functions of rats with type 2 diabetes mellitus are obviously improved. Therefore, the low-G I coarse cereal bean meal replacement powder has good effects of controlling blood sugar and blood fat.

Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and / or administering insulin levels in the patient.

This invention discloses a composition for the prevention or treatment of diabetes and its application, relating to the field of pharmaceutical technology. The composition is a combination of any of the following components: a mitochondrial protectant, a vanadium compound, and a hormone / pheromone. It can improve pancreatic β-cell activity and control fasting blood glucose, satiety blood glucose, glucose tolerance, and insulin levels within dietary dosage ranges.